Hypogonadism: Therapeutic Risks, Benefits, and Outcomes.
Med Clin North Am
; 102(2): 361-372, 2018 Mar.
Article
em En
| MEDLINE
| ID: mdl-29406064
ABSTRACT
Hypogonadism is a common condition defined by the presence of low serum testosterone levels and hypogonadal symptoms, and most commonly treated using testosterone therapy (TTh). The accuracy of diagnosis and appropriateness of treatment, along with proper follow-up, are increasingly important given the large increase in testosterone prescriptions and the recent concern for cardiovascular (CV) risk associated with TTh. In March of 2015, the US Food and Drug Administration required that testosterone product labels disclose a potential CV risk, despite the evidence base for this association being weak and inconclusive. However, TTh may improve CV outcomes rather than increase risks.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Testosterona
/
Hipogonadismo
Tipo de estudo:
Diagnostic_studies
/
Etiology_studies
/
Risk_factors_studies
Limite:
Humans
/
Male
Idioma:
En
Revista:
Med Clin North Am
Ano de publicação:
2018
Tipo de documento:
Article
País de afiliação:
Estados Unidos